






























































Accepted author’s manuscript. Published in final edited form as:  
Pharmacology 2021; 106(5-6): 244-253. Publisher DOI: 10.1159/000515908 
 
Utilizing artificial intelligence to manage COVID-19 scientific evidence torrent 1 
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Introduction: The SARS-CoV-2 pandemic has led to one of the most critical and 34 
boundless waves of publications in the history of modern science. The necessity to 35 
find and pursue relevant information and quantify its quality is broadly acknowledged. 36 
Modern information retrieval techniques combined with artificial intelligence (AI) 37 
appears as one of the key strategies for COVID-19 living evidence management. 38 
Nevertheless, most AI projects that retrieve COVID-19 literature still require manual 39 
tasks. Methods: In this context, we present  a novel, automated search platform, called 40 
Risklick AI, which aims to automatically gather COVID-19 scientific evidence and 41 
enable scientists, policy makers and healthcare professionals to find the most relevant 42 
information tailored to their question of interest in real time. Results: Here, we compare 43 
the capacity of Risklick AI to find COVID-19-related clinical trials and scientific 44 
publications in comparison to clinicaltrials.gov and Pubmed in the field of 45 
pharmacology and clinical intervention. Discussion: The results demonstrate that 46 
Risklick AI is able to find COVID-19 evidences more effectively, both in terms of 47 
precision and recall, compared to the baseline platforms. Hence, Risklick AI could 48 
become a useful alternative assistant to scientists fighting the COVID-19 pandemic. 49 




The SARS-CoV-2 pandemic resulted in one of the largest waves of publications and 52 
clinical trials in the history of modern science, with the number of articles doubling 53 
every 20 days and unprecedented clinical trial rate [1–3] . In this context, it has become 54 
virtually impossible for scientists, policy makers and healthcare workers to keep up 55 
with the speed at which data are generated. Moreover, this situation limited the 56 
possibilities offered to professionals involved in the pandemic to read entire articles 57 
thoroughly, as well as to properly evaluate the limitations of the data. In addition, this 58 
outburst of publications also impacted the average quality of research papers [4,5].  59 
The necessity to effectively gather scientific evidence that encompasses only relevant 60 
information with acceptable quality has been one of the most important modern 61 
challenges in science. This issue has become strikingly evident throughout the COVID-62 
19 crisis. In this context, artificial intelligence (AI) appears to be the best strategy to 63 
seek the most relevant scientific evidence in a minimum amount of time [6,7]. AI-based 64 
strategies are now required to diminish time of research, increase performance, and 65 
reduce errors and oversights in the research of references performed by scientists and 66 
health professionals. The proliferation of AI-based initiatives to address the COVID-19 67 
pandemic has resulted in the creation of numerous technologies, such as LitCovid and 68 
the COVID-NMA Project, among others [8,9]. However, most of the developed COVID-69 
19 tools, such as the cited examples, require manual steps in the analytic process. 70 
Hence, a fully automated, AI-based efficent tool is still missing in the context of the 71 
COVID-19 pandemic in order to optimize the access and the management of specific 72 
knowledge and research results. 73 
In this context, we developed a novel, automated scientific evidence management 74 
platform called Risklick AI. The tool aims to gather and manage COVID-19-related 75 
 
 
literature using natural language processing (NLP), a technology allowing computers 76 
to process and analyze large amounts of data expressed in natural language [10–12]. 77 
The tool combines classic statistical word frequency methods, so called bag-of-words, 78 
with state-of-the-art masked language models [13–15]. Hence, using artificial 79 
intelligence, Risklick AI allows computers to analyze human language with more 80 
meaning than with the usual processed and programed responses. In this study, we 81 
compare the capacities of Risklick AI to find COVID-19-related clinical trials compared 82 
to clinicaltrials.gov [16] and scientific publications in comparison with Pubmed. We 83 
compared query outcomes of Risklick AI to clinicaltrials.gov and Pubmed on COVID-84 
19 pharmacologically relevant treatments, as considered by the authorities [17]. Here, 85 
we demonstrate that Risklick AI represents the more effective technology with the 86 
potentiality to assist scientists in finding and pursuing relevant COVID-19-related 87 
scientific evidences. 88 




Data collection 91 
On a daily basis, Risklick AI collects and updates clinical trials data on from wide 92 
sources such as clinical trials registries and datasets from World Health Organization 93 
(WHO) [18]. Moreover, publications’ metadata like titles, abstracts, journal names, 94 
publication date, digital object identifier number and others are collected and updated 95 
from sources like PubMed, Embase, BioRxiv and MedRxiv from “Living Evidence on 96 
COVID-19,” and “CORD-19” datasets (19) . 97 
Technology 98 
All the data for clinical trials and publications is preprocessed to align to a predefined 99 
data format and added to Elasticsearch, which serves as a full text search and analytics 100 
engine for clinical trials and publications. The indexed data and queries are normalized 101 
using a pipeline of text preprocessing techniques like tokenization, lowercasing, stop 102 
words removal, and reducing words to their root form. The indices are maintained in a 103 
Elasticsearch cluster. The index model parameters are tuned using a set of manually 104 
annotated queries. The similarity measure was computed using the divergence from 105 
randomness model (DFR) with the term frequency normalization set to 20.0 [19]. A 106 
detailed description of the pipeline is provided by Ferdowsi et al [15]. 107 
 108 
To increase the recall of relevant documents to user query, we apply query expansion 109 
techniques using a COVID-specific ontology of standardized medical terms, their 110 
synonyms, classes, and sub-classes engineered by clinical trial domain experts [20]. 111 
For instance, once the user search for heparin, the query automatically expands to all 112 
three major of heparin: unfractionated heparin (UFH), low molecular weight heparin 113 
(LMWH), ultra-low-molecular weight heparin (ULMWH), and their trade names based 114 
on COVID-specific ontology (e.g. Nadroparin, Fraxiparin, Fraxodi, Calciparine, 115 
 
 
Bemiparin, Zibor, Ivor, Enoxaparin, Clexane, lovenox, Fragmine, Dalteparin, 116 
Dociparstat).  117 
 118 
Experimental setup 119 
At the time of analysis, more than 1800 interventional studies linked to COVID-19 were 120 
available on clinicaltrials.gov. In addition, more than 48’500 COVID-19-related 121 
publications were available on Pubmed. In order to compare Risklick AI’s performance 122 
with other COVID-related search platforms, we defined and used a common set of 123 
search queries, which were executed on a specific day for all platforms. To assess our 124 
clinical trial search engine, we compared Risklick AI with the most advanced and 125 
biggest clinical trial registry–– clinicaltrials.gov. In addition to COVID-19 cases, 126 
clinicaltrials.gov covers all of COVID-19 clinical trials from other registries like 127 
clinicaltrialsregister.eu and chichtr.org, as specified by clinicaltrials.gov 128 
(https://clinicaltrials.gov/ct2/who_table). Hence, clinicaltrials.gov appears as the 129 
adapted gold-standard to allow comparison with Risklick AI. 130 
The day the queries are run, the platform retrieves the latest dataset from 131 
clinicltrials.gov and it is indexed in the Risklick AI platform. The comparison comprises 132 
of only interventional clinical trials having unique clinicaltrials.gov identifier (NCT-133 
number). To compare the clinical trials found by the different types of queries, data 134 
from Risklick AI, clinicaltrials.gov, and corona-trials.org are collected for categories like 135 
antibiotic, anticoagulant ,and antiviral, as well as more fine granular queries for specific 136 
drugs like Remdesivir, Tocilizumab, Azithromycin, Hydroxychloroquine, and Heparin 137 
(suppl. Table 1).  138 
 Risklick AI and PubMed were then compared regarding their publications search 139 
performance. Before running the query, the latest COVID-19-related publications are 140 
retrieved from PubMed using the predefined queries in the Institute of Social and 141 
 
 
Preventive Medicine (ISPM) Bern and added to a new index in Risklick AI [21]. This 142 
way we ensure that the queries executed on a specific day on PubMed and Risklick AI 143 
retrieve publications based on the same data distribution for the specific day on both 144 
platforms. To compare the scientific publications found by the different queries, data 145 
from Risklick AI and Pubmed were collected for antithrombotic, dexamethasone and 146 
Favipiravir (suppl. Table 2). 147 
All the drug categories used in this study (antibiotic, antithrombotic, antiviral, and 148 
anticoagulant) are resumed in suppl. Table 3. 149 
 150 
Validation 151 
Verification and validation procedures were performed by two separate and 152 
independent immunologists. All clinical trials and scientific publications were analyzed 153 
and verified manually. To optimize the result comparison between the different search 154 
tools, recall (the number of positive class predictions made out of all positive examples 155 
in the dataset), precision (the number of positive class predictions that actually belong 156 
to the positive class), and F1-score (single score that balances both the concerns of 157 
precision and recall in one number) were calculated [22]. 158 
 159 
Data analysis 160 
Retrieved publications were individually and manually scored as true-positive or false-161 
positive. Graphs were created using Prism 8.0. 162 




Comparison search performance for clinical trials 165 
The capacity of Risklick AI to retrieve COVID-19-related clinical trials was analyzed. 166 
When compared to clinicaltrials.gov and covid-trials.org, regarding its capacity to find 167 
COVID-19-related clinical trials, Risklick AI found more raw clinical trials than other 168 
tools for different categories of treatments such as antibiotic anticoagulant and antiviral 169 
(Figure 1A). In average, Risklick found 1.9-times more clinical trials than 170 
clinicaltrials.gov for these 3 treatments, and 8.2-times more than covid-trials.org for 171 
these same 3 treatments. When investigating key molecules of each category, such 172 
as Hydroxychloroquine, Remdesivir, Azithromycin, Tocilizumab or Heparin (Figure 173 
1B), Risklick AI presented more raw output compared to the 2 other research tools. No 174 
clinical trial connected to COVID-19 was found (n.d.) on covid-trials.org for the Heparin 175 
query. 176 
In order to compare the search capacity of Rislick AI in comparison with 177 
clinicaltrials.gov, COVID-19-related search was restricted to the same database, using 178 
only clinical trials registered on clinicaltrials.gov. This strategy was applied for both 179 
drug classes and specific drugs. Using Hydroxychloroquine data for illustration, we first 180 
segregated publications found only by Risklick AI or clinicaltrials.gov (“Unique”) from 181 
publications found by both tools (“Common”) (Figure 1C). Then, unique publications 182 
were analyzed and separated between true–positive (“True”) and false-positive 183 
(“False”) results (figure 1D). Ultimately, we calculated the total number of true positives 184 
of the publications by adding the categories common and unique along with true-185 
positive (Figure 1E).  186 
We further analyzed accuracy of both tools for drug classes. There, Risklick AI showed 187 
a higher number of relevant clinical trials for antibiotic (8.9%) (Figure 2A-C), 188 
 
 
anticoagulant (29.4%) (Figure 2D-F), and antiviral drugs (47.2%) (Figure 2G-I) 189 
associated with COVID-19 in comparison to clinicaltrials.gov on the same reference 190 
database. Recall, precision and F1 score measures for the 3 drugs categories were 191 
systematically higher for Risklick AI compared to clinicaltrials.gov (suppl Table 3). The 192 
detailed analysis reveals that the higher score of Risklick AI is due to a higher number 193 
of true-positives (that is, higher recall), and a lower number of false-positives (that is, 194 
higher precision) in the unique findings cohort relative to clinicaltrials.gov (Figure 195 
2B,E,H). The analysis was then extended to specific drugs. There, Hydroxychloroquine 196 
(Figure 1 C-E), Tocilizumab (Figure 3A-C), and Heparin (Figure 3D-F) all presented a 197 
higher number of relevant clinical trials associated with COVID-19 compared to 198 
clinicaltrials.gov. Again, the higher score of Risklick AI is due to a higher number of 199 
true-positives, and a lower amount of false-positives unique findings in comparison to 200 
clinicaltrials.gov for these three drugs (Figure 1D and Figure 2 B,E). Regarding 201 
Azithromycin, the same number of relevant clinical trials was found in both search tools 202 
(Figure 3G-I). However, in opposition to clinicaltrials.gov, Risklick AI uncovered no 203 
false-positive outcomes (Figure 3H). Ultimately, no difference was observed between 204 
Risklick AI and clinicaltrials.gov regarding Remdesivir (Suppl. Fig.1). When taken 205 
together, Risklick AI presented an average recall of 99.25% compared to 86.61% for 206 
clinicaltrials.gov. By extension, Risklick AI also presented a F1 score of 97.59%, while 207 
clinicaltrials.gov had 88.57% (Table 1). 208 
 209 
Risklick AI search performance regarding COVID-19-related publications 210 
 211 
The data retrieval was extended to COVID-19-related scientific publications by 212 
comparing Risklick to Pubmed search capacities. We restricted the search to the 213 
Pubmed database using Boolean search tool. There, we investigated the number of 214 
 
 
relevant publications restricted to COVID-19 for antithrombotic (+61.4%) (Figure 4A-215 
C), Dexamethasone (+114.3%) (Figure 4 D-F) and Favipiravir (+38.3%) (Figure 4 G-216 
I). As for the comparison with clinicaltrials.gov, the superiority of Risklick AI compared 217 
to Pubmed is due to a more important number of true-positives, and a lower amount of 218 
false-positive unique findings (Figure 4 B,E,H). Taken together, the Risklick search 219 
presented an average recall of 86.66% compared to 61.26% for Pubmed. In addition, 220 
the average F1 score for Risklick reached 90.28% compared to 71.68% for Pubmed 221 
(Table 1). 222 
 223 
Evaluation of Risklick AI’s publication search tool 224 
 225 
Risklick AI offers the possibility to find COVID-19-related publications using Boolean-226 
based search or NLP-based search methods and further combining the results of both 227 
methods. Here, we compare the capacity of each technology to find COVID-19-related 228 
publications. Hence, Boolean-based search (“Risklick bool”), NLP-based search 229 
(“Risklick NLP”), and NLP-based search supplemented with pre-print publications 230 
(“Risklick NLP+PP”) were compared for antithrombotic (Figure 5 A-C), 231 
Dexamethasone (Figure 5 D-F), and Favipiravir (Figure 5 G-I). The searches in Risklick 232 
AI and clinicaltrials.gov are run based on same dataset for the specific day and based 233 
on same queries. Overall, Risklick AI NLP and Risklick NLP+PP offer more 234 
publications than Boolean-based search (+23.7% and +118.3%, respectively), 235 
although each search strategy presents various rates of false-positive outcomes 236 
(Figure 5 B,E,H). Used synchronously, both search methods offer a more complete, 237 
pertinent overview of currently available literature on the given treatments linked to 238 
COVID-19. Regarding clinical trials, clinicaltrials.gov uses Medical Subject Headings 239 
(MeSH) terms for query expansion, but does not match misspelled or differently spelled 240 
 
 
words for a disease or intervention. Risklick AI combines query expansion technology 241 
based on ontology defined by experts together with NLP techniques. The NLP 242 
techniques allow us to better deal with misspelled and similarly spelled words, which 243 




The COVID-19 outbreak has resulted in one of the biggest waves of publications in the 246 
history of modern science [2,23]. In these conditions, it has became clear that COVID-247 
19 data retrieval and monitoring would be one of the main challenges of the current 248 
and future pandemics [24]. To address this dilemma, we automatically gathered and 249 
centralized all COVID-19 scientific information from scattered sources on a daily basis. 250 
Several intelligent algorithms and models were then developed to retrieve query 251 
relevant scientific evidences from a centralized database. Both Boolean and NLP-252 
based search methods have been used to find query relevant scientific evidences.     253 
In this study, the search performance of our methodology was compared to 254 
clinicaltrials.gov when screening the same database of clinical trials. Several 255 
molecules were selected to this purpose based on their connection to COVID-19 trials 256 
currently performed worldwide, as well as their important number of citations in the 257 
scientific literature. Overall, the abilities of the Risklick AI method to find relevant clinical 258 
trials against specific intervention queries were higher than the reference search tools, 259 
both for drug classes as for single treatments. Interestingly, the Risklick AI performance 260 
was largely due to a higher true-positive and lower false-positive outcome in 261 
comparison to clinicaltrials.gov. We believe this is due to the power of the full text 262 
search engine combined with the Boolean model plus the improved semantics brought 263 
by the COVID ontology. 264 
When extended to COVID-19-related publications, Risklick AI also confirmed a 265 
superior search capability compared to the medical reference tool Pubmed, using the 266 
Boolean search engine. By extension, we compared the capacities of Risklick AI to 267 
find the scientific COVID-19 literature for pharmacological keywords using the Boolean 268 
and NLP approach. Molecules and categories selected for this analysis were chosen 269 
 
 
based on their relevance to COVID19. These molecules were not engaged into 270 
numerous clinical trials as for molecules chosen in the clinicaltrials.gov comparison. 271 
There, we observed that both strategies offered a broad overview of key search articles 272 
with a high proportion of unique outcomes. In addition, we also confirmed the capacity 273 
of Risklick AI to find preprint (PP) literature database with a high true-positive outcome, 274 
allowing for broad search perspectives in a context of permanent novelty not covered 275 
by Pubmed. 276 
On the one hand, Boolean search is still used in recent platforms like PubMed, 277 
Embase, and others. On the other hand, recent advancements in NLP and full-text 278 
searches enable better gathering of queries, sentences, and documents. These 279 
developments reduce the need for preprocessing and normalization steps and they 280 
improve the quality of context-based searches.  281 
Our methodology offers two search interfaces to find documents on the same datasets: 282 
one for Boolean search and one for NLP context-based search. This way users can 283 
arbitrarily combine the results of both approaches and thus improve precision and 284 
recall of their results. By extension, the evaluation results demonstrate the potential of 285 
the proposed method to help scientists and decision makers to triage key information 286 
out of the torrent of scientific papers from the COVID-19 pandemic. Consequently, 287 
Risklick AI could play a key role in the development of novel drugs and strategies 288 
targeting COVID-19, and could therefore become an important ally in fields such as 289 
pharmacology and epidemiology to organize the medical response against the SARS-290 
CoV-2 virus. Moreover, in perspective of the current situation, Risklick AI could play an 291 
primordial role in the monitoring of all COVID-19 vaccines effectiveness, particularly in 292 
perspective of the numerous variants and associated serotypes of SARS-CoV-2. By 293 
extension, Risklick AI could offer significant advantages in the data management of 294 
 
 
other diseases and pathologies for clinicians and fundamental researchers. Since the 295 
underlying technology is generic, the framework can be used in other diseases and 296 
areas to manage relevant scientific evidences.  297 
  298 
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FIGURE LEGENDS 371 
Figure 1. Risklick AI clinical trials outcome for COVID-19 compared to other web-372 
based resource registries. (A, B) Total raw number of clinical trials found by Risklick 373 
AI compared to other registries for drug classes (A) and specific treatments (B) used 374 
against COVID-19. (C-E) Analysis of search capacity of registered clinical trials by 375 
Risklick AI and clinicaltrials.gov based on the same dataset for hydroxychloroquine. 376 
Clinical trials were separated between common and unique outcomes (C). Unique 377 
outcomes were validated and separated between true-positive (True) and false-378 
positive (False) results (D). Final total number of true positive clinical trials is comprised 379 
of the addition of common findings and unique, true-positive findings (E). n.d, no data. 380 
  381 
 
 
Figure 2. Risklick AI clinical trials search capacity for drug classes connected to 382 
COVID-19 compared to clinicaltrials.gov based on the same dataset. (A-C) 383 
Analysis of search capacity of registered clinical trials by Risklick AI and 384 
clinicaltrials.gov on the same database for antibiotic drugs. Clinical trials were 385 
separated between common and unique outcomes (A). Unique outcomes were 386 
validated and separated between true-positives (true) and false-positives (False) 387 
results (B). The final total number of true positive clinical trials is the addition of 388 
common findings and unique, true-positive findings (C). The same procedure was 389 
performed for anticoagulant (D-F) and antiviral (G-I) drugs. 390 
  391 
 
 
Figure 3. Risklick AI clinical trials search capacity for specific treatments 392 
associated with COVID-19 in comparison with clinicaltrials.gov on the same 393 
dataset. (A-C) Analysis of search capacity of registered clinical trials by Risklick AI and 394 
clinicaltrials.gov on the same dataset for Tocilizumab. Clinical trials were separated 395 
between common and unique outcomes (A). Unique outcomes were validated and 396 
separated between true-positive (true) and false-positive (wrong) results (B). Total final 397 
number of true positive clinical trials is the addition of common findings and unique, 398 
true-positive findings (C). The same procedure was performed for Heparin (D-F) and 399 
Azithromycin (G-I). n.s, no data. 400 
  401 
 
 
Figure 4. Risklick AI publication search capacity for specific treatments 402 
associated with COVID-19 compared to Pubmed on the same publication 403 
dataset.(A-C) Analysis of search capacity of COVID-19-related publications by 404 
Risklick AI and Pubmed on the same publication dataset for antithrombotic. 405 
Publications were separated between common and unique outcomes (A). Unique 406 
outcomes were validated and separated between true-positive (true) and false-positive 407 
(wrong) results (B). Total final number of true positive publications is the addition of 408 
common findings and unique, true-positive findings (C). Same procedure was 409 
performed for Dexamethasone (D-F) and Favipiravir (G-I). 410 
  411 
 
 
Table 1. Risklick AI, clinicaltrials.gov and Pubmed average recall, precision and 412 
F1 score for all the different molecules and treatments groups searched.  413 
  414 
 
 
Figure 5. Risklick AI publication search capacity for specific treatments 415 
associated with COVID-19 using Boolean or Natural-language processing (NLP) 416 
search methods. (A-C) Analysis of search capacity of COVID-19-related publications 417 
by Risklick AI using Boolean search tool (bool), Natural-language processing (NLP) 418 
research tool, and NLP with the database extended to pre-print (PP) publications for 419 
antithrombotic drugs. Publications were separated between common and unique 420 
outcomes (A). Unique outcomes were validated and separated between true-positive 421 
(true) and false-positive (wrong) results (B). Total final number of true positive 422 
publications is the addition of common findings and unique, true-positive findings (C). 423 
The same procedure was performed for Dexamethasone (D-F) and Favipiravir (G-I). 424 
 425 
